TP53 Status and Chemotherapy in Ovarian Cancer
Author Information
Author(s): Kupryjanczyk Jolanta, Kraszewska Ewa, Ziolkowska-Seta Izabela, Madry Radoslaw, Timorek Agnieszka, Markowska Janina, Stelmachow Jerzy, Bidzinski Mariusz
Primary Institution: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Hypothesis
The study aims to define profiles of ovarian cancer patients who benefit most from taxane-platinum therapy versus platinum-based therapy based on TP53 status.
Conclusion
Taxane-platinum therapy is particularly effective in patients with TP53(+) tumors or those older than 53 years, while platinum-based therapy may be equally effective in younger patients with TP53(-) tumors.
Supporting Evidence
- Taxane-platinum therapy enhanced the probability of complete remission in TP53(+) patients.
- Patients older than 53 years showed better outcomes with taxane-platinum therapy.
- Platinum-based therapy was equally effective in younger patients with TP53(-) tumors.
Takeaway
This study looks at how different treatments work better for different types of ovarian cancer based on a specific protein called TP53. Some patients do better with one treatment than the other.
Methodology
The study compared the effectiveness of platinum-based therapy and taxane-platinum therapy in ovarian cancer patients with different TP53 statuses using retrospective data analysis.
Potential Biases
Potential bias due to the non-randomized nature of the study and differences in treatment protocols.
Limitations
The study is non-randomized and retrospective, which may introduce bias due to differences in patient characteristics.
Participant Demographics
The median age of participants was 53 years, with a mix of FIGO stages IIB-IV.
Statistical Information
P-Value
p = .018 for complete remission in TP53(+) group
Confidence Interval
[1.22, 8.83] for complete remission in TP53(+) group
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website